 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial |
| Tadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe, |
|
Intest Res. 2018;16(3):494-498. Published online July 27, 2018 DOI: https://doi.org/10.5217/ir.2018.16.3.494 |
|
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial Intestinal Research. 2018;16(3):494  Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis Alimentary Pharmacology & Therapeutics. 2007;26(11-12):1509-1520 Mo1689 SIBDQ Score Does Not Predict the Need for Dose Escalation of Infliximab in Inflammatory Bowel Disease Patients Gastroenterology. 2012;142(5):S-660 Su1225 Concomitant Elemental Diet Therapy Is Effective in Sustaining Infliximab Scheduled Maintenance Therapy in Patients With Crohn's Disease to Prevent Loss of Response Gastroenterology. 2013;144(5):S-433 94 Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial Gastroenterology. 2013;144(5):S-22 Safety and effectiveness of endoscopic pneumatic dilatation+infliximab combined therapy in stenosing Crohn disease Digestive and Liver Disease. 2006;38:S15 Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review The American Journal of Gastroenterology. 2009;104(3):760-767 Infliximab dose escalation beneficial for RA PharmacoEconomics & Outcomes News. 2006;496(1):3-3 Infliximab dose escalation not uncommon during first year in RA PharmacoEconomics & Outcomes News. 2006;494(1):4-4 Sa1974 Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels Gastroenterology. 2016;150(4):S421 |
